Skip to main content Skip to navigation

Dr Hardip Sandhu

Supervisor Details

For >17 years, Dr Sandhu has focussed on investigating therapy-induced cardiovascular injury by applying her expertise in safety pharmacology and cardiovascular diseases and injury development to address TICvI. She is building on her “proof-of-principle” preliminary work presented briefly in the projects described above and aims to deliver TICvI screening models that will aid the PhamaIndustry in identifying cardiovascular adverse effects of their candidate drugs, allowing them to make changes and avoid wasting valuable resources developing a drug candidate that would ultimately fail in the clinic due to its cardiovascular adverse effects. The TICvI screening models could also be used in a healthcare setting to monitor patients who are undergoing therapy known to be associated with cardiovascular adverse effects.

Research Interests

The key research projects that Dr Sandhu is currently leading include: “Diagnostic miRNA biomarkers for TICvI” and “Vascular TICvI model exploiting the G-protein coupled receptors (GPCRs) signalling”. These research projects are the instinctive progression of my current research expertise, combining genomic, molecular biology and vascular safety pharmacology techniques to determine the complex links between drug safety interactions and pathophysiological disease conditions.

Scientific Inspiration

My scientific inspiration is my line manager Prof Helen Maddock. She has been a truly supportive mentor and shown me how to be a good researcher and colleague. Her support guidance has built my research profile, as she has always encouraged me to develop and succeed while balancing family life.


MIBTP Project Details

Current Projects (2025-26)

Co-supervisor on a project with Dr Isadora Clivatti Furigo.